Gene Technology Regulations 2007

The Regulations operationalise several central regulatory concepts from the Act. Each concept is defined and constrained by specific provisions and schedules.

• Exempt dealings (reg 6; Schedule 2). Exempt dealings are dealings with GMOs listed in Schedule 2 Part 1 and performed in defined host/vector systems in Schedule 2 Part 2, provided they meet the subsidiary criteria in reg 6(1)(b)-(e). Core constraints include conformity with technical/procedural guidelines under s 27(d) of the Act (reg 6(1)(c)), no intentional release (reg 6(1)(d)), and exclusion where a retroviral vector can transduce human cells (reg 6(1)(e)). Schedule 2 is detailed about permitted hosts, vectors, donor nucleic acid restrictions (e.g. toxin coding, characterisation), and culture-volume limits (10 litres per vessel in many items).
• Notifiable low risk dealings (NLRDs) (regs 12-13; Schedule 3). NLRDs are a distinct lower-tier regulatory regime where prior IBC notification to the Regulator suffices instead of a licence (reg 13(1)). Schedule 3 Part 1 lists dealings that are NLRDs, including certain modifications of whole animals, plants in enclosed facilities, host/vector combinations not in Schedule 2, and other specified situations (Sched 3 Part 1 items (a)-(i)). Schedule 3 Part 2 lists dealings that are explicitly not NLRDs (for example, cloning toxins under LD50 thresholds, high-level expression of toxin genes, certain viral vector manipulations) and therefore require licensing (Sched 3 Part 2). The NLRD route imposes facility containment and personnel training requirements and allows the Regulator to require further information (reg 13).
• Facility certification and organisation accreditation (regs 14-17; regs 41-42 transitional). Facilities used for NLRDs must be Regulator‑certified to an appropriate physical containment level, usually PC2 or higher as necessary (reg 13(2)(a)). Organisations carrying out regulated dealings may require accreditation under the Act; the Regulations allow refusal of certification or accreditation where applicants fail to provide mandatory information under ss 85 and 93 (regs 15, 17). Transitional deeming provisions treat certain existing facilities and organisations as certified/accredited for limited periods, provided they comply with Regulator guidelines (regs 41-42).
• Risk assessment and consultation (regs 9-10). The Regulator must take into account previous regulatory assessments (subject to s 45 of the Act) and a list of ecological and biological risks (reg 10(1)). A set of Commonwealth authorities are prescribed consultative bodies for advice (reg 9).
• Ministerial and Regulator discretion in emergency and vaccine contexts (reg 6A). A targeted provision allows Ministerial approval of persons or classes for vaccine-related dealings, and Ministerial approval of technical/procedural guidelines, after consultation with the Health Minister; the Minister must publish approved guidelines on the department website (reg 6A(3)-(5)). The COVID‑19 provision is an express, time-limited adaptation of the licensing exemption architecture to a public health emergency context.
• Procedural timelines and exclusions (reg 8). The Regulations provide: decision periods for licence applications (90 or 170 days depending on Act Part), and carve out days not to be counted, including weekends/public holidays, periods awaiting requested information, public hearing periods, confidentiality pause periods, and days while awaiting ethics committee advice (reg 8(1)-(3)).

Technical thresholds and operational rules are central: “characterised” nucleic acid, toxin LD50 cutoffs (100 μg/kg), a 10‑litre per-vessel threshold for culture volumes, lists of permitted hosts and vectors, and constraints on viral sequences are all operational levers set out in the Schedules (Sched 2 Part 1, Part 2; Sched 3). The Regulations also adopt many Commonwealth regulation provisions for committee governance by reference (Parts 4-6; regs 18-36), signalling that committee functions and procedures align with Commonwealth practice.

Mechanically, the Regulations shift much of the compliance burden onto institutions and IBCs to ensure proper notification, containment, personnel competence and documentation before certain categories of work can proceed without a licence (reg 13). The Regulator retains review and information‑request powers and prescriptive guidance over certification/accreditation outcomes (regs 13(3)-(4), 15, 17).

The Regulations affect a set of identifiable actors, and allocate costs, decision rights and obligations among them.

• Researchers and project supervisors. Those proposing or supervising work that creates or handles GMOs must ensure dealings fall into an appropriate regulatory category (exempt, NLRD, licensed). For NLRDs, project supervisors must receive IBC written confirmation as to the type of dealing and personnel competence before work starts (reg 13(1)(b)). Where an activity falls outside exempt/NLRD categories (Schedules 2 and 3), researchers must pursue a licence under the Act (reg 6(1) note; reg 12(1) note).
• Institutional Biosafety Committees (IBCs). IBCs are gatekeepers for NLRDs: they must notify the Regulator in the approved form and must certify in writing to the person and project supervisor that the dealing is of the listed kind and that personnel have appropriate training and experience (reg 13(1)). IBCs also face direct obligations to provide further information if the Regulator issues a notice (reg 13(3)-(4)).
• Organisations and facility operators. Facilities must be Regulator‑certified to at least PC2 (or another level the Regulator deems suitable) to host NLRDs (reg 13(2)(a)(i)-(ii)). Organisations seeking accreditation to carry out certain higher‑risk dealings must supply information under s 93; failure to supply may lead to refusal (reg 17). Existing facilities/organisations that previously received Genetic Manipulation Advisory Committee notices are treated as certified/accredited for limited transitional periods, conditioned on compliance with Regulator guidelines (regs 41-42).
• The Regulator. The Regulator interprets and enforces the licensing, certification and NLRD processes. The Regulator decides licence applications within regulated timeframes (reg 8), prescribes forms, accepts or refuses certification/accreditation where applicants fail to provide required information (regs 15, 17), may require further information regarding NLRDs (reg 13(3)-(4)), and must keep specified records of notified dealings and GM products (reg 39). The Regulator also issues technical and procedural guidelines under s 27(d) of the Act which are enforceable conditions of exemptions and NLRDs (reg 6(1)(c); reg 13(2)(b)).
• The Minister and Health Minister. The Minister has a specific discretionary role under the COVID‑19 dealing exemption: after consulting the Health Minister, the Minister may approve classes of persons and technical/procedural guidelines for COVID‑19 vaccine‑related dealings; the Minister must publish approved guidelines on the department website (reg 6A(3)-(5)). This confers a political oversight and authorisation role for vaccine-related activity.
• Inspectors. Inspectors are given identity card requirements (reg 40) and, although the Regulations do not enumerate particular enforcement powers, the Regulator’s ability to require information and to refuse certification/accreditation creates roles for inspection and compliance verification. Section references in the Regulations point to the Act for inspection and enforcement powers (e.g. reg 6 note; reg 39).
• Third‑party consultative and technical agencies. The Regulations prescribe a list of Commonwealth authorities to be consulted where the Act requires technical advice, including FSANZ, AQIS, NHMRC, NICNAS Director (now under Industrial Chemicals Act context), APVMA and the Therapeutic Goods Administration (reg 9). These agencies influence regulatory assessments and timelines by supplying advice referred to in s 50(3) and s 52(3) of the Act.

Who pays: regulated organisations and IBCs incur the direct costs of compliance: preparing notifications, maintaining certified facilities to prescribed physical containment levels, developing or following approved technical/procedural guidelines, supplying requested information within Regulator timeframes, and possibly seeking licences. The Minister and Regulator allocate administrative costs within their agencies to consult prescribed Commonwealth authorities, publish guidelines, and maintain registers and decision timelines.

What behaviour changes: institutions will structure projects to fit within exempt or NLRD categories where feasible to avoid full licence processes; they will strengthen IBC pre‑approval procedures, maintain training records and containment infrastructure to the Regulator’s standards, and document donor nucleic acid characterisation to meet Schedule 2 and Schedule 3 thresholds (e.g. avoiding uncharacterised toxin-producing nucleic acid).

The Regulations allocate explicit duties, permissions and limited rights; most duties flow to IBCs, project supervisors, organisations, and the Regulator.

Duties on IBCs and persons proposing NLRDs (reg 13):

• Notify the Regulator in the Regulator’s approved form of a proposed notifiable low risk dealing before it is undertaken (reg 13(1)(a)).
• Notify the person and project supervisor in writing that (i) the proposed dealing is of the kind in Schedule 3 Part 1, and (ii) personnel have appropriate training and experience, and (iii) the notification to the Regulator has been made (reg 13(1)(b)(i)-(iii)).
• Provide further information to the Regulator where required by written notice; the recipient must provide the information by the period specified (reg 13(3)-(4)).

Duties on facility operators and organisations (reg 13(2); regs 14-17; Scheds 2-3):

• Conduct NLRDs only in facilities certified by the Regulator to at least physical containment level 2, or at any other containment level the Regulator considers suitable, and ensure facilities are of appropriate design for that dealing (reg 13(2)(a)(i)-(ii)).
• Comply with applicable technical and procedural guidelines under s 27(d) of the Act when transporting GMOs (reg 13(2)(b); reg 6(1)(c)(ii)).
• For exempt dealings in Schedule 2, ensure the dealing does not involve unintended categories (e.g. intentional release, retroviral vectors able to transduce human cells) and complies with donor nucleic acid restrictions and culture volume limits where specified (reg 6(1); Sched 2).
• For certification or accreditation applications, supply the information required under s 85 (facilities) or s 93 (organisations) within any notice period specified; failure without reasonable explanation authorises the Regulator to refuse certification/accreditation (regs 15, 17).

Duties on the Regulator and Minister:

• Decide licence applications within prescribed timeframes,90 days for applications governed by Part 5 Div 3, and 170 days for those under Part 5 Div 4,subject to exclusions of specified days (reg 8(1)-(3)).
• Consider specified risk assessment matters, including previous assessments and the GMO’s potential to harm organisms and ecosystems, transfer genetic material, persist or spread, have environmental advantage, or be toxic, allergenic, or pathogenic; and to consider both short- and long-term horizons (reg 10(1)-(2)).
• Prescribe and consult Commonwealth authorities for technical advice (reg 9).
• Keep prescribed particulars in the Record of GMO and GM Product Dealings for notified NLRDs and GM products (reg 39(1)-(2)).

Limited rights and procedural protections:

• Applicants have a statutory timeframe within which the Regulator must decide (reg 8). The calculation of that timeframe excludes days when applicants have been asked for information, confidentiality-related pauses, public hearing periods, and days awaiting committee advice (reg 8(2)-(3)). This creates a procedural right to a decision within a bounded time provided applicants respond to requests and the Regulator proceeds without waiting for late ethics advice.
• Applicants may have review rights under the Act: refusals to certify or accredit are reviewable decisions (regs 15, 17 notes referencing Part 12 Division 2 of the Act). One Regulation notes that persons affected by committee appointment decisions may apply to the Administrative Appeals Tribunal for review (reg 38 note). The Regulations themselves do not specify the full review process; they reference the Act and Commonwealth regulations.

Recordkeeping duty (reg 39):

• For NLRD notifications, the Regulator must record the organisation name, the kind of NLRD (per Schedule 3 Part 1), the identifying project name, and the notification date (reg 39(1)(a)-(d)).
• For GM products in designated notifications, the prescribed particulars include producer name, description with reference to the applicable WA Act and product common name, parent organism names, trait and introduced gene identity, decision effective date under the applicable Act, and details of conditions attaching to the permission (reg 39(2)(a)-(e)).

Inspector identity card content is prescribed (reg 40):

• Must display a recent photograph, the date of issue and the period of validity (reg 40(a)-(c)).

The Regulations also create duties to follow the Regulator’s technical and procedural guidelines where those are approved under s 27(d) and, for COVID‑19 vaccine dealings, to follow Minister‑approved guidelines published on the department website (regs 6(1)(c), 6A(2)(c), 6A(3)(b)-(5)). These duties make compliance dependent on guidelines that can change over time, placing an ongoing compliance monitoring duty on organisations.

The Regulations themselves set out procedural prerequisites and consequences for non‑compliance but do not create a schedule of monetary or custodial penalties in the text provided. Instead, they rely on the Act for offences, enforcement powers and review mechanisms, while prescribing how the Regulator must operate and what information it must keep. Key enforcement and sanction‑relevant mechanisms in the Regulations include:

• Refusal of certification or accreditation where applicants fail to provide required information. The Regulator may refuse to certify a facility if the applicant fails to supply information required under s 85(1) within the notice period and offers no reasonable explanation (reg 15). The Regulator may refuse to accredit an organisation in like circumstances under s 93(1) (reg 17). The accompanying notes expressly state that such refusals are reviewable decisions (regs 15 and 17 notes referencing Part 12 Division 2 of the Act).
• Regulator information‑gathering and compliance checks. The Regulator may, by written notice, require the notifying IBC or persons/organisations involved in an NLRD to give further information to be satisfied the dealing is an NLRD (reg 13(3)-(4)). Such notices create an administrative enforcement lever: failure to comply with notices is likely to be treated as non‑compliance under the Act (the Regulations do not specify the sanction; the Act contains offence and enforcement provisions).
• Record requirements. The Regulator must keep particular records of NLRDs and GM products (reg 39). Maintaining and publishing these records facilitates transparency and creates a factual basis for enforcement under the Act.
• Inspector identity and deployment. The Regulations prescribe the form of inspector identity cards (reg 40). While the Regulations do not set out inspectors’ powers, requiring identifiable credentials is consistent with administrative enforcement practice under the Act, which confers inspection powers elsewhere. The card content requirement facilitates lawful exercise of inspection powers and addresses procedural fairness in enforcement encounters.
• Licensing and NLRD regime itself as a control. By defining narrow exemptions and NLRD categories and by listing dealings that are not NLRDs (Schedule 3 Part 2), the Regulations increase the set of activities that require licences. If an entity undertakes dealing outside permitted exemptions or NLRD categories without a licence, enforcement under the Act can follow.

What the Regulations do not do here is prescribe specific criminal penalties or fine amounts; these are located in the Act. The Regulations also do not delineate an enforcement schedule or graduated penalty system; they instead set administrative consequences (refusal of certification/accreditation; requirement to supply information; recordkeeping) and rely on the Act for substantive sanctions.

The Regulations also create procedural protections potentially relevant in enforcement contexts. For example, in timing decisions the Regulator must not count days where the applicant has sought confidentiality protections and the Regulator is waiting on confidentiality determinations or allowed review periods (reg 8(2)(d)). The Regulator may specify a reasonable period for ethics advice and proceed without it if not received by a specified time (reg 8(3)). These provisions balance a Regulator’s enforcement/decision powers against procedural fairness to applicants.

Finally, the COVID‑19 exemption (reg 6A) introduces Ministerial discretion to expand exemptions in an emergency context. That discretion may alter which dealings are subject to full licence enforcement, creating both expedited compliance pathways and potential enforcement risk if guidelines or approvals are not followed.

The Regulations are cross‑referential and expressly subordinate to the Gene Technology Act 2006 (WA). They also interact with Commonwealth regulations and other Commonwealth and State laws.

Cross‑reference to Commonwealth regulations and Acts:

• The Regulations preserve numbering parity with Commonwealth gene technology regulations (regs 3A, 3B), and repeatedly adopt or reference Commonwealth regulation provisions for committee governance and procedure (Parts 4-6 and multiple notes). The frequent notes,“regulation X of the Commonwealth regulations provides…”,mean that, for many committee appointment and procedural rules, the Commonwealth text supplies the operative detail (regs 18-36 notes).
• The Regulations refer to Commonwealth legislative instruments and regimes in substance: reg 6A lists relevant dealing categories that include those authorised under a Commonwealth GMO licence and those specified in an emergency dealing determination under s 72B of the Commonwealth Act, or declared by Commonwealth regulations to be NLRDs or exempt dealings. Thus, Commonwealth classification decisions and emergency determinations directly affect whether a dealing is an exempt dealing in WA under reg 6A(1)(a-d).

Interface with other State and Commonwealth Acts:

• The Regulations explicitly state that an exemption from provisions of the Act does not preclude the application of another law of the State, Commonwealth or another State (reg 6 note). This keeps overlapping regulatory regimes (for example, biosafety, quarantine, agricultural chemical approvals) operative.
• For registration/GM product records, reg 39 prescribes particulars to be recorded with reference to an applicable Act, explicitly naming the Agricultural and Veterinary Chemicals (Western Australia) Act 1995 as the “applicable Act” in reg 39(2)(b)(i). This shows an intended administrative cross‑link between GMO regulatory records and pesticide/agvet regulatory decisions.
• Reg 9 prescribes Commonwealth authorities to be consulted for technical advice. That list includes Food Standards Australia New Zealand, Australian Quarantine and Inspection Service, National Health and Medical Research Council, the National Industrial Chemicals Notification and Assessment Scheme Director (under a Commonwealth Act), the Australian Pesticides and Veterinary Medicines Authority, and the Therapeutic Goods Administration (reg 9). Where the Act requires consultation (ss 50(3)(c) and 52(3)(c)), these agencies’ views must be sought, which integrates gene technology decisions with food safety, quarantine, chemical assessment and therapeutic regulatory regimes.
• The COVID‑19 regulation (reg 6A) brings in the Health Minister under the Health Services Act 2016 for Ministerial consultation. The reg also permits Ministerial approval of technical guidelines that can be those as in force under the Commonwealth Act (reg 6A(4)). The Minister’s requirement to publish guidelines on the department website (reg 6A(5)) creates a public‑administrative linkage between State ministerial approval and Commonwealth technical frameworks.

Overlap and potential duplications:

• Because the Regulations adopt Commonwealth committee procedures and consult Commonwealth authorities, there is functional integration but also potential duplication or complexity when Commonwealth and State classifications differ. The Regulations attempt to align numbering and, in many committee matters, to defer to Commonwealth practice (regs 3A; regs 18-36 notes), reducing the risk of divergent internal procedures but not eliminating possible substance differences,e.g. the COVID‑19 exemption is a State addition (reg 6A) that expressly references Commonwealth authorisations.
• The Regulations require compliance with technical and procedural guidelines “as in force from time to time under section 27(d) of the Act” (reg 6(1)(c); reg 13(2)(b)). Those guidelines may change and interact with other technical standards such as AS/NZS 2243.3:2002 referenced in Schedule 1 (Sched 1 item 7(b)(i)). Organisations must therefore monitor guideline updates at multiple decision levels.

Transitional interactions:

• The transitional provisions (regs 41-42) deem certain existing facilities and organisations certified/accredited for limited periods, subject to continued compliance with Regulator guidelines and sections of the Act (regs 41(1)-(3); 42(1)-(2)). That eases short‑term regulatory transitions from previous advisory arrangements to the Act’s certification/accreditation framework.

In short, the Regulations do not sit in isolation: they import Commonwealth procedural detail, reference Commonwealth regulatory classifications and emergency determinations, cross‑link to health, agvet and chemical laws, and explicitly preserve other laws’ application even when an activity is exempt under the Act’s licensing scheme (reg 6 note). Organisations must therefore map compliance not only to these Regulations and the Act but to the intersecting Commonwealth instruments and State Acts referenced.

The compilation table and in-text amendment note show the Regulations’ publication and one later amendment recorded in the materials provided.

• Original instrument: Gene Technology Regulations 2007, published 27 July 2007, commenced 28 July 2007 (compilation table; reg 1-2).
• Amendment recorded in the compilation table: Gene Technology Amendment Regulations 2020 (SL 2020/145). The amendment particulars in the compilation table indicate r 1 and r 2 commenced 28 August 2020 and the other Regulations (other than rr 1 and 2) commenced 29 August 2020 (compilation table).
• Textual evidence of amendment: Regulation 6A (Particular dealings relating to COVID‑19 vaccine exempt dealings) is expressly noted as inserted by SL 2020/145 r. 4 (reg 6A heading includes “[Regulation 6A inserted: SL 2020/145 r. 4.]”). That indicates a targeted 2020 amendment inserting an emergency/time-sensitive exemption pathway for COVID‑19 vaccine‑related activities, tying State exemptions to Commonwealth licences, emergency determinations, Commonwealth classifications and Ministerial approvals.

Nature of the 2020 amendment:

• The added reg 6A establishes a mechanism for the State Minister, after consulting the Health Minister, to approve persons or classes and approve technical/procedural guidelines for dealings relating to COVID‑19 vaccines (reg 6A(3)). It defines “relevant dealing” to include Commonwealth‑authorised GMO licences, emergency dealing determinations under s 72B of the Commonwealth Act, Commonwealth regulations that declare a dealing to be NLRD or exempt, or dealings included in the Commonwealth GMO Register (reg 6A(1)). It also requires publication of approved technical/procedural guidelines on the department website (reg 6A(5)). The amendment thus adapts the licensing exemptions to an emergency vaccine rollout context in 2020.

Other amendment signals:

• The Regulations contain numerous notes stating that particular provisions of the Commonwealth regulations apply to committee appointments, resignations, disclosure of interests, meeting procedures, quorum and voting (regs 18-36 notes). These are not necessarily amendments but indicate that the State instrument was framed to mirror Commonwealth rules and to refer to Commonwealth regulations for committee governance. The numbering regulation (reg 3A) confirms the intentional alignment of numbering and headings with Commonwealth regulations.

No other amendments are visible in the provided text or the compilation table beyond SL 2020/145. The compilation table shows only the original 2007 Regulations and the 2020 amendment instrument. There is no detailed record in the provided text of prior amendments, repeals, or variations beyond this.

Implications of the amendment history:

• The insertion of reg 6A in 2020 illustrates that the Regulations are capable of targeted, rapid adaptation in response to a public health emergency. The amendment couples State Ministerial approval and publication duties with Commonwealth authorisations and classifications, creating a hybrid waiver pathway for vaccine‑related work. Practically, regulated entities should watch for future similar amendments that may create conditional exemptions tied to national emergency mechanisms.

The Regulations themselves do not contain case law or a litigation record. The instrument as provided includes no judicial decisions or litigation annotations. The text does however reference administrative review and the potential for review under the Administrative Appeals Tribunal in relation to committee appointments, as an example of avenues for challenge (reg 38 note).

What the Regulations record about review and challenge:

• The notes to regs 15 and 17 refer to refusal to certify or accredit being reviewable decisions under Part 12 Division 2 of the Act (regs 15, 17 notes). This signals an administrative review route available to applicants under the Act rather than the Regulations themselves setting out review procedures.
• Reg 38’s note says the Commonwealth regulations provide that a person whose interests are affected by a decision in relation to the appointment of a member to a committee under those regulations may apply to the Administrative Appeals Tribunal for review (reg 38 note). That note indicates that committee appointment decisions, to the extent governed by the Commonwealth regulations adopted by reference, are amenable to AAT review.

Absence of recorded litigation in the instrument:

• The provided material does not list any cases, judicial interpretations, appeals, or reported litigation arising from the Regulations. It does not cite any decisions interpreting specific schedules or thresholds (for example the 10‑litre rule, LD50 cutoffs, or “characterised” nucleic acid). Consequently, there is no litigation history to summarise from the Regulations text supplied.

Practical consequence for practitioners and researchers:

• Because there is no litigation history recorded here, uncertainties about ambiguous terms or the interpretation of particular Schedule thresholds would need to be addressed through direct engagement with the Regulator, through administrative review channels where available (refusals to certify or accredit), or in the courts should a dispute arise and a litigant challenge be mounted. The Regulations’ frequent deferrals to Commonwealth regulations for committee and procedural matters suggests that some procedural review rights are exercised through Commonwealth administrative law channels (AAT review for committee appointments per reg 38 note).

Note on scope: The lack of litigation history in the instrument does not mean there have been no legal disputes relevant to gene technology in Western Australia or nationally; it means the Regulations’ text does not record any cases, and practitioners should check legal databases and the Act’s consolidated annotations for any case law interpreting the Act or these Regulations.

The Regulations contain many specific traps for the unwary. Below are precise operational pitfalls drawn from the text.

1. Exemptions are conditional and narrow (reg 6; Schedule 2). A dealing listed in Schedule 2 Part 1 is not automatically exempt. It must also:

   • Not involve a genetic modification beyond those described (reg 6(1)(b)).
   • Be conducted in accordance with applicable technical and procedural guidelines under s 27(d) (reg 6(1)(c)).
   • Not involve an intentional release into the environment (reg 6(1)(d)).
   • Not involve a retroviral vector able to transduce human cells (reg 6(1)(e)). Failure to satisfy any one of these conditions pulls the dealing out of exemption and may require a licence.

2. Schedule 2 donor nucleic acid and culture-volume limits bite (Sched 2 Part 1 items 4-5). Exempt host/vector dealings are limited to cases where donor nucleic acid meets several constraints:

   • Not derived from pathogens or must be characterised and not known to alter host range, transmission, virulence etc. (Sched 2 Part 1 item 4(2)(a)).
   • Must not code for toxins with LD50 <100 μg/kg, and high-expression intentions for toxins with LD50 ≥100 μg/kg are excluded (Sched 2 Part 1 item 4(2)(b)-(c)).
   • Not be uncharacterised nucleic acid from toxin-producing organisms (Sched 2 Part 1 item 4(2)(d)).
   • Viral sequences are generally excluded unless missing an essential gene for replication and incapable of correcting defects leading to replication competent virions (Sched 2 Part 1 item 4(2)(e)). The 10-litre culture per vessel cap is a hard quantitative limit for many exempt dealings; producing >10 litres can convert the activity into a non-exempt or NLRD depending on the device and facility (Sched 2 Part 1 item 4(1)).

3. Notifiable low risk dealings (NLRDs) require prior IBC notification and written confirmation (reg 13(1)). A project supervisor relying on an NLRD pathway must have the IBC both notify the Regulator and certify in writing personnel competence and the dealing’s categorisation before work commences. Starting work without the written IBC confirmation risks being an unlicensed dealing.

4. The NLRD list and the “not notifiable” list are separate and interacting (reg 12; Schedule 3). Some dealings that superficially look low risk are explicitly excluded from the NLRD pathway (Sched 3 Part 2), including cloning of toxin genes with LD50 <100 μg/kg, high-level toxin expression, uncharacterised toxic nucleic acid cloning, certain viral manipulations, and any dealing involving intentional introduction of a GMO into a human being (Sched 3 Part 2 items (a)-(m)). Practitioners must consult both lists; an item appearing in Part 1 can still be excluded if it also appears in Part 2, per reg 12(1)(a) note.

5. COVID‑19 exemption caveats (reg 6A). The COVID‑19 dealing exemption is not blanket. It only applies to “relevant dealings” (those authorised under Commonwealth GMO licences, emergency dealing determinations under the Commonwealth Act, declared by Commonwealth regulations to be NLRDs or exempt, or included in the GMO Register) and only if the person or class is approved by the WA Minister and the dealing follows Minister‑approved technical/procedural guidelines (reg 6A(1)-(3)). The Minister must consult the Health Minister and publish approved guidelines (reg 6A(3)-(5)). A Commonwealth authorisation alone might not be enough in WA unless State Ministerial approval and guideline compliance are secured.

6. Timeframes are suspended for several events (reg 8). The Regulator’s decision clocks (90 or 170 days depending on Act Part) pause for weekends/public holidays, periods awaiting requested information, public hearing periods, confidentiality-related waiting, and time while ethics advice is pending. Practitioners who expect a rapid decision must respond promptly to information requests and cannot assume the statutory calendar days automatically ensure a speedy decision if they delay or confidentiality/review processes are invoked (reg 8(1)-(3)).

7. Failure to provide information can lead to refusal of certification/accreditation (regs 15, 17). The Regulator may refuse certification or accreditation where required information under s 85 or s 93 is not provided within the notice period and no reasonable explanation is given (regs 15, 17). That refusal is reviewable but can interrupt operations.

8. “Characterised” is a specific but potentially subjective standard (reg 3 definition). The Regulations define “characterised, in relation to nucleic acid, means nucleic acid that has been sequenced and in respect of which there is an understanding of potential gene products or potential functions” (reg 3). For donors to meet “characterised” requirements in Schedules 2 and 3, sequencing and sufficient functional understanding are prerequisites. The degree of “understanding” may be contested and could drive requests for more information or disagreements with the Regulator.

9. The Regulations leave many particulars to guidelines under s 27(d) of the Act. Exemption and NLRD compliance require conformity with those guidelines for containment and transport (reg 6(1)(c); reg 13(2)(b)). Because guidelines are “as in force from time to time”, compliance is ongoing and dynamic; organisations must track guideline changes and apply new versions quickly.

10. Multiple overlapping approvals may be required (reg 6 note; reg 39). Exemption under these Regulations does not preclude other laws. For GM products intended for supply, recordkeeping must reference the Agricultural and Veterinary Chemicals (WA) Act where relevant (reg 39(2)(b)(i)). A dealing compliant with these Regulations may still need separate approvals under agvet, therapeutic goods, quarantine or local environmental laws.

11. Transitional deeming is time limited and conditional (regs 41-42). Facilities and organisations that were previously certified/accredited under the Genetic Manipulation Advisory Committee are deemed certified/accredited only for limited periods (typically 1-2 years) and only while they maintain compliance with Regulator guidelines. Failure to progress to full certification/accreditation risks losing the deemed status.

12. Committee procedure details are in Commonwealth regulations (regs 18-36 notes). Practitioners seeking to influence or predict committee behaviour must read the corresponding Commonwealth regulations, because the State Regulations frequently refer to them for appointment, disclosure and voting rules.

In sum, the principal gotchas are conditional exemptions, objective thresholds that can be contested (characterisation, LD50, culture volumes), dependence on guidelines, multiple overlapping regulatory regimes, and procedural timing pauses. Entities should map their activity precisely against Schedule entries, prepare robust documentation of nucleic acid characterisation and training, and maintain certified facilities.

Compliance under these Regulations is managed through three main administrative tracks: (1) ensuring that the dealing falls into an exempt, notifiable low risk, or licensable category; (2) ensuring facility and personnel prerequisites (certification/accreditation and containment) are met; and (3) ensuring timely responses to Regulator information requests and recordkeeping obligations. Practical steps, cross-referenced to the Regulations, follow.

1. Classify the dealing accurately

   • Step: Compare the proposed activity against Schedule 2 (exempt dealings and host/vector lists) and Schedule 3 (NLRDs and not‑NLRDs). Do not assume similarity to prior projects; check the literal Schedule entries (Sched 2 Part 1 & Part 2; Sched 3 Part 1 & Part 2).
   • Why: An error in classification exposes the organisation to carrying out unlicensed activities. Reg 6(1) defines the conditions for exempt dealings; reg 12 and reg 13 define NLRDs.

2. If relying on an exempt dealing (Schedule 2)

   • Step: Confirm the donor nucleic acid meets Schedule 2 Part 1 constraints: characterised status, toxin LD50 thresholds, absence of uncharacterised toxin-producing sequences, and that any viral sequences lack essential replication genes and cannot correct defects (Sched 2 Part 1 items 2-3).
   • Step: Ensure the dealing will not involve intentional environmental release, and no retroviral vector capable of transducing human cells will be used (reg 6(1)(d)-(e)).
   • Step: Verify culture volume limits (no more than 10 litres per vessel where specified) and host/vector combinations are from Schedule 2 Part 2 (Sched 2).
   • Why: Exemptions depend on these technical conditions. Document sequence data, LD50 information, and vector maps to evidence compliance.

3. If relying on a notifiable low risk dealing (Schedule 3)

   • Step: Obtain IBC approval and have the IBC notify the Regulator in the form approved by the Regulator before commencing (reg 13(1)(a)). Ensure the IBC issues written confirmation to the person and project supervisor that the dealing is of the listed kind and that personnel are suitably trained (reg 13(1)(b)).
   • Step: Confirm the facility is Regulator‑certified to at least PC2 (or as otherwise required) and that facility design is appropriate (reg 13(2)(a)).
   • Step: For transport of GMOs, follow applicable technical and procedural guidelines under s 27(d) of the Act (reg 13(2)(b), reg 6(1)(c)(ii)). Keep evidence of guideline compliance.
   • Step: Be prepared to respond promptly to any Regulator notice requiring further information; the Regulator may ask IBCs, persons, or organisations to provide additional information (reg 13(3)-(4)).
   • Why: Failure to follow these steps voids the NLRD pathway and could render the dealing unlicensed.

4. Facility certification and organisation accreditation

   • Step: If certifying a facility or seeking accreditation, prepare the full documentation required under ss 85 (facility) and 93 (organisation) and respond within any notice periods. Understand that failure to provide required information without a reasonable explanation authorises refusal (regs 15, 17).
   • Step: For existing facilities and organisations that held prior Genetic Manipulation Advisory Committee notices, map existing certification to the transitional deeming timelines (2 years for many PC2 facilities; 1 year for PC3/PC4 or PC2 Large Scale facilities) and ensure compliance with Regulator guidelines throughout (regs 41-42).
   • Why: Certification and accreditation underpin eligibility for NLRDs and influence licensing decisions. Early attention prevents refusal risks.

5. Risk documentation and Regulator consultation

   • Step: Prepare risk assessments that explicitly address the matters listed in reg 10: previous assessments, capacity to harm organisms, ecosystem impacts, potential for horizontal gene transfer, potential to persist or spread, environmental advantage, toxicity/allergenicity/pathogenicity, and consider both short- and long-term horizons (reg 10(1)-(2)).
   • Step: Where the Act requires it, expect consultation with prescribed Commonwealth authorities (reg 9). Proactively gather information relevant to those authorities’ expertise (food safety, quarantine, chemical assessment, therapeutic goods).
   • Why: Robust risk dossiers reduce delays and lower the likelihood of adverse findings.

6. Time management for licence decisions

   • Step: Be aware of the Regulator’s decision timeframes (90 or 170 days depending on the Act Part) and the events that suspend the clock (reg 8(1)-(3)). Respond quickly to information requests and avoid invoking confidentiality processes unless necessary; confidentiality review pauses counting days.
   • Why: Efficient responses keep the decision process within statutory windows; poor responsiveness allows the Regulator to legitimately extend decision timelines.

7. Documentation and records

   • Step: Maintain records sufficient for the Regulator’s Record of GMO and GM Product Dealings. For NLRDs, the Regulator will record organisation name, the kind of dealing (Schedule 3 Part 1), an identifying project name, and notification date (reg 39(1)). For GM products included in designated notifications, assemble the particulars required by reg 39(2).
   • Step: Keep IBC notifications and written confirmations on file; these will be required in audits or in response to Regulator notices.
   • Why: Accurate records satisfy statutory recordkeeping obligations and are necessary in case of Regulator queries or audits.

8. Training and competence

   • Step: Document training and experience for personnel who will conduct NLRDs; IBCs must confirm personnel qualifications as part of their written notification (reg 13(1)(b)(ii)).
   • Why: Personnel competence is an explicit precondition for NLRD approvals.

9. Follow guidelines and Ministerial approvals for special cases

   • Step: For COVID‑19 vaccine-related dealings, obtain any required state Minister approvals for persons/classes and ensure work is in accordance with Minister‑approved technical and procedural guidelines, published on the department website (reg 6A(2)-(5)). For other areas, monitor the Regulator’s guidelines under s 27(d) which are binding for certain exemptions (reg 6(1)(c); reg 13(2)(b)).
   • Why: Some exemptions are conditional on Ministerial approval or guideline compliance; absence of published approval or guideline adherence defeats the exemption.

10. Anticipate overlapping legal requirements

    • Step: Determine whether other laws apply (industry‑specific approvals, agvet, quarantine, therapeutics). Exemption under the Regulations does not negate the need to comply with other State, Commonwealth or local laws (reg 6 note; reg 39 cross‑references to Agricultural and Veterinary Chemicals (WA) Act).
    • Why: Regulatory compliance often requires multiple approvals; start the mapping early to avoid bottlenecks.

11. Plan for inspection and identity verification

    • Step: Ensure staff expect inspectors to present identity cards with photo, date of issue and validity period (reg 40). Maintain open records and documentation to facilitate inspection.
    • Why: Clear inspection procedures minimise operational interruptions and support demonstrable compliance.

12. Prepare for escalation and review

    • Step: If certification/accreditation is refused or other administrative decisions adversely affect the organisation, review rights exist under the Act (regs 15, 17 notes referencing Part 12 Division 2). For committee appointment decisions, AAT review may be available (reg 38 note). Document grounds and timelines for review and engage legal advice early.
    • Why: Administrative review is the primary internal route to contest Regulator decisions.

In practical terms, those responsible for compliance should appoint a regulatory lead to:

• Map each project to a Sched/Reg provision,
• Maintain a checklist of required sequencing/characterisation data and LD50 metrics,
• Keep contemporaneous training and IBC documentation,
• Subscribe to Regulator and Minister publications to catch guideline updates, and
• Institute turn‑around procedures to answer Regulator information requests quickly.

Following these steps aligns actions with the Rules the Regulations prescribe: classification (Scheds 2-3), IBC notification (reg 13), facility certification (reg 13(2); regs 14-17; regs 41-42), and documentation for the Regulator’s records (reg 39).